Clinical trialNCT06248515RecruitingPhase 2Interventional

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

SponsorGeorgetown UniversityEnrollment18Thymic CarcinomaThymoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy. The main question it aims to answer is: • What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma? Participants will: * receive a fixed dose of 10 mg/kg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity * have regular blood tests, scans, and examinations to monitor their health. * have blood and a biopsy of their tumor for research purposes.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Chul Kim, MD
Chul.Kim@gunet.georgetown.edu
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Stanford Cancer Institute
Palo Alto, California, United States
Heather A Wakelee, MD
Recruiting
Lombardi Comprehensive Cancer Center, Georgetown University
Washington D.C., District of Columbia, United States
Chul Kim, MD
Recruiting
University of Chicago Medical Center
Chicago, Illinois, United States
Marina Garassino, MD
Recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Martin Gutierrez, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Sacituzumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Apr 2024
Primary completion: 30 Apr 2026
Completion: 31 Dec 2026
Last update posted: 27 Jan 2026
Registered enrollment: 18
Registry id: NCT06248515

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.